Helix BioPharma Files Interim Financials, Highlights Oncology Pipeline Progress

Helix BioPharma Corp., a clinical-stage oncology company, announced the filing of its unaudited interim financial statements for the three-month period ended October 31, 2025. The filings, which include the management's discussion and analysis and certifications from the CEO and CFO, are publicly available on the company's SEDAR+ profile and its corporate website. This routine financial disclosure provides investors with a snapshot of the company's financial health as it advances its pipeline of cancer therapies.

The importance of this filing extends beyond standard financial reporting, as it coincides with updates on Helix's research and development efforts. The company is focused on developing treatments for cancers that are currently difficult to treat. Its lead candidate, L-DOS47, is an antibody-enzyme conjugate designed to make tumors more sensitive to existing anti-cancer treatments. This drug has completed Phase Ib studies in non-small cell lung cancer, a significant milestone that demonstrates progress toward potential future therapies. The company's pipeline also includes next-generation bi-specific antibody-drug conjugates built on the same targeting technology as L-DOS47.

Further development is underway with two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator targeting post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability comparable to intravenous administration. These candidates represent innovative approaches to expanding treatment options for patients with advanced cancers. The financial statements and accompanying documents are accessible on the company's profile at https://www.sedarplus.ca and on its website at https://www.helixbiopharma.com/filings-and-financials/.

For the oncology industry and investors, Helix's interim filings provide crucial transparency into how the company is allocating resources toward its clinical programs. The progress of L-DOS47 and the development of LEUMUNA and GEMCEDA highlight the company's strategy to address unmet medical needs in cancer treatment. Successful advancement of these therapies could potentially improve outcomes for patients with hard-to-treat cancers, impacting both healthcare and the biopharmaceutical sector. Investors and stakeholders can monitor these developments through the company's public disclosures, which include forward-looking statements subject to risks and uncertainties detailed in its periodic reports.